Cargando…

Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis

The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteopor...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hashimi, Leith, Klotsche, Jens, Ohrndorf, Sarah, Gaber, Timo, Hoff, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299520/
https://www.ncbi.nlm.nih.gov/pubmed/37373840
http://dx.doi.org/10.3390/jcm12124147
_version_ 1785064384593133568
author Al-Hashimi, Leith
Klotsche, Jens
Ohrndorf, Sarah
Gaber, Timo
Hoff, Paula
author_facet Al-Hashimi, Leith
Klotsche, Jens
Ohrndorf, Sarah
Gaber, Timo
Hoff, Paula
author_sort Al-Hashimi, Leith
collection PubMed
description The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteoporosis, TBS detects restricted bone quality. To investigate the influence of an additional evaluation of TBS on patients’ treatment strategy decisions, we enrolled 292 patients, with a high proportion of patients with secondary osteoporosis, from one outpatient unit over one year. Patients eligible for BMD measurement had the option to opt-in for TBS measurement. We analyzed demographic data, leading diagnoses, bone metabolism parameters, and results of BMD and TBS measurements. More than 90% of patients consented to TBS measurement. TBS measurement influenced the decision in approximately 40% of patients with a treatment indication for anti-osteoporotic drugs. We demonstrate that depending on the underlying disease/risk spectrum, 21–25.5% of patients had an unremarkable BMD measurement with poor bone quality shown in the TBS measurement. In patients with secondary osteoporosis, the use of TBS supplementary to DXA seems useful to better assess fracture risk and, thus, to initiate therapy for osteoporosis in these patients in time.
format Online
Article
Text
id pubmed-10299520
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102995202023-06-28 Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis Al-Hashimi, Leith Klotsche, Jens Ohrndorf, Sarah Gaber, Timo Hoff, Paula J Clin Med Article The trabecular bone score (TBS) can be determined in addition to the Dual Energy X-ray Absorptiometry (DXA) for bone mineral density (BMD) measurement to diagnose, evaluate, and stratify bone loss and decide on appropriate treatment in patients at risk. Especially in patients with secondary osteoporosis, TBS detects restricted bone quality. To investigate the influence of an additional evaluation of TBS on patients’ treatment strategy decisions, we enrolled 292 patients, with a high proportion of patients with secondary osteoporosis, from one outpatient unit over one year. Patients eligible for BMD measurement had the option to opt-in for TBS measurement. We analyzed demographic data, leading diagnoses, bone metabolism parameters, and results of BMD and TBS measurements. More than 90% of patients consented to TBS measurement. TBS measurement influenced the decision in approximately 40% of patients with a treatment indication for anti-osteoporotic drugs. We demonstrate that depending on the underlying disease/risk spectrum, 21–25.5% of patients had an unremarkable BMD measurement with poor bone quality shown in the TBS measurement. In patients with secondary osteoporosis, the use of TBS supplementary to DXA seems useful to better assess fracture risk and, thus, to initiate therapy for osteoporosis in these patients in time. MDPI 2023-06-20 /pmc/articles/PMC10299520/ /pubmed/37373840 http://dx.doi.org/10.3390/jcm12124147 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Al-Hashimi, Leith
Klotsche, Jens
Ohrndorf, Sarah
Gaber, Timo
Hoff, Paula
Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title_full Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title_fullStr Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title_full_unstemmed Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title_short Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis
title_sort trabecular bone score significantly influences treatment decisions in secondary osteoporosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299520/
https://www.ncbi.nlm.nih.gov/pubmed/37373840
http://dx.doi.org/10.3390/jcm12124147
work_keys_str_mv AT alhashimileith trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis
AT klotschejens trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis
AT ohrndorfsarah trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis
AT gabertimo trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis
AT hoffpaula trabecularbonescoresignificantlyinfluencestreatmentdecisionsinsecondaryosteoporosis